Skip to main content

Concurrent Enumeration of CD34+ and CD3+ Cells in Allogeneic Apheresis Collections Using a New Flow Cytometry Method

   

Donor lymphocyte infusions (DLI) are commonly used to prevent or treat relapse after allogeneic stem cell transplantation. DLIs may be collected through a separate apheresis procedure or derived from excess mobilized stem cell grafts. The latter approach is routine and requires quantification of both CD34+ stem/progenitor cells and CD3+ T lymphocytes. Currently, these measurements are performed in two separate assays by an independent laboratory.

We evaluated ACCELLIX™, a new flow cytometry method, that enables in-house simultaneous enumeration of CD34+ and CD3+ cells in a single assay with the potential to streamline graft characterization, reduce turnaround time, and decrease resource utilization.

Concurrent Enumeration of CD34+ and CD3+ Cells

Download the Poster

Complete the form below to access the poster, which will be sent directly to your email after submission. By providing your information, you agree to receive additional emails from bioMérieux about Cell & Gene Therapy quality control.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.

   

Related Content

Comparative Evaluation of Automated

Poster

Comparative Evaluation of Automated and Conventional Flow Cytometry Methods for Leukapheresis Characterization Upon Cryopreservation Process

This poster compares the analytical performance of a conventional flow cytometry method with the automated ACCELLIX™ platform for the characterization of lymphocyte subpopulations in cryopreserved leukapheresis samples.

Learn More

Specialty

Cell & Gene Therapy Solutions

Bring simplicity and automationg to Cell & Gene Therapy manufacturing through advanced technologies that enhance quality, safety and efficiency; to achieve faster product release.

Learn More

Product

ACCELLIX

Cell and Gene Therapy Quality Control is critical. It doesn’t have to be difficult. 

Stringent process controls are needed to monitor critical parameters throughout the cell therapy manufacturing process, and these laborious tests are challenging to scale. The Accellix Automated Cell Phenotyping Platform eliminates these limitations and automates your entire QC workflow from sample preparation to data analysis, generating rapid cell phenotyping results directly in the manufacturing suite.get in 

Learn More